ARTICLE BY LOUIS

  • Some Biopharma Haven’t Caught Outsourcing Enthusiasm
    Some Biopharma Haven’t Caught Outsourcing Enthusiasm

    I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

  • Leadership At “The Best CMO In The World”
    Leadership At “The Best CMO In The World”

    An Exclusive Interview on Leadership with Samsung BioLogics President & CEO Tae Han Kim.

  • Can Bayer Innovate the Incubator For Japan?
    Can Bayer Innovate the Incubator For Japan?

    There’s not much of a biotechnology industry in Japan. That doesn’t deter Shunichi Takahashi, head of Bayer's Open Innovation Center Japan (ICJ). He’s innovating the incubator to mine the abundant research at universities there.

  • The Drums Of BIO 2015: Dollars, Nano and Data
    The Drums Of BIO 2015: Dollars, Nano and Data

    Among the drumbeat of discussions at BIO 2015, three sounds reverberated above all: the first came from the bass drum of money; next was the razor-sharp tones of the nanotech snare drum; and hitting the cymbals for exclamation was “the whole digital field interacting with pharma and bio."

  • Samsung BioLogics: How To Build A CMO Business
    Samsung BioLogics: How To Build A CMO Business

    In this exclusive interview with Outsourced Pharma, Tae Han Kim, PhD, president and CEO of Samsung BioLogics, shares his story of how he selected the biologics contract-manufacturing industry, the building of his business, and his first customers.

  • Super Quality Accidental Collisions at BIO 2015
    Super Quality Accidental Collisions at BIO 2015

    At first blush, the BIO 2015 theme of “Super” doesn’t sound all that, well, super. But after meeting a super hero of the industry who warns of the need to prepare for super quality accidental collisions, the theme comes into full focus.

  • Marking The Present And Promise of Biomarkers
    Marking The Present And Promise of Biomarkers

    Biomarkers are becoming an industry unto themselves: they have their own FDA tables and World Congress, and have been before the Supreme Court. They also provide outsourcing companies with growing business opportunities. At the same time, it’s good practice to temper enthusiasm with a reality-check on the real-world status of the development and application of any science. 

  • A Cost Measurement Pharma Can Live With (CROs/CMOs, Too)
    A Cost Measurement Pharma Can Live With (CROs/CMOs, Too)

    Sometimes one finds help in unusual places. This might be one of those times for Pharma, and the place could be AdverseEvents. And Pharma can turn to a more usual partner — CROs/CMOs — to positively influence what AdverseEvents measures.

  • CROs In A Business Exchange With Silicon Valley?
    CROs In A Business Exchange With Silicon Valley?

    As an applied economic theoretic, by driving out inefficiencies from the current model used by researchers to find and contract with CROs, the Science Exchange should improve the business model for drug discovery. But will all parties — Pharma/Bio, CROs and individual researchers — benefit equally? 

  • Corning A Force For Flow Reactors
    Corning A Force For Flow Reactors

    On a morning in Shanghai when the air is anything but, Dr. Yi Jiang of Corning is crystal clear on his view of the biopharmaceutical industry’s transitioning from batch to advanced-flow reactors.

More FromLouis Garguilo
Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.